Robert T. Schooley, MD
Professor of Medicine
Head, Division of Infectious Diseases
University of California San Diego
San Diego, California

Research Topics

• Pathogenesis and therapy of HIV-1 infection
  
  
  

Lecture and Writing Topics

• New antiretroviral drugs
• HIV pathogenesis
• When to start and change antiretroviral therapy
• Immune-based therapy for HIV infection
• Primary HIV infection
• AIDS vaccine development
  
  
  

Current Professional Summary

Dr Schooley is a Professor of Medicine at University of California San Diego. Dr. Schooley is also a member of the Board of Directors of the International AIDS Society–USA.


Committees and Organizations

• Chair, Executive Committee, AIDS Clinical Trials Group
• Member, Board of Directors, International AIDS Society–USA
• Antiretroviral Therapy Guidelines Panel, International AIDS Society–USA
• Member, Department of Health and Human Services Antiretroviral Therapy Guidelines Panel
• Association of American Physicians (1995–)
• American Society for Clinical Investigation (1990–)
  
  
  

Honors and Awards

• Bonfils-Stanton Award for Science in Colorado
• Colorado AIDS Project Distinguished Service Award
  
  
  

Education

• Washington and Lee University, BS (1970)
• The Johns Hopkins University, MD (1974)
• The Johns Hopkins Hospital, Medical Residency (1974–1976)
  
• Infectious Disease Fellowships, National Institute of Allergy and Infectious Diseases and Massachusetts General Hospital (1976–1981)
  
  
  

Selected Publications

1. Connick E, Marr DG, Zhang XQ, Clark SJ, Saag MS, Schooley RT, Curiel TJ. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retroviruses. 1996;12:1129-1140.
2. Uherova P, Connick E, MaWhinney S, Schlichtemeier R, Schooley RT, Kuritzkes DR. In vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from persons infected with human immunodeficiency virus type 1. J Infect Dis. 1996;174:483-489.
3. Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St. Clair MH, and the protocol 34,225-02 Collaborative Group. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2', 3'-dideoxycytidine combination therapy. J Virol. 1996;70:5922-5929.
4. Schooley RT, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St. Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF and the Wellcome Resistance Study Collaborative Group. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared to zidovudine monotherapy. J Infect Dis. 1996;173:1354-1366.
5. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Team. N Engl J Med. 1996;335:1081-1090.
6. Hughes MD, Daniels MJ, Fischl MA, Kim S and Schooley RT. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS clinical trials group. AIDS. 1998;12:1823-1832.
7. Mitsuyasu RT, Skolnik PR, Cohen SR, Conway B, Gill MJ, Jensen PC, Pulvirenti JJ, Slater LN, Schooley RT, Thompson MA, Torres RA, Tsoukas CM, Salgo M, Delora P, Shear M, Beattie D, Nestle J, Wolfarth C, Craig C, Duff FP. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV 15355 Study Team. AIDS. 1998;12:F103-F109.
8. Saag MS, Sonnerborg A, Torres RG, Lancaster D, Gazzard BG, Schooley RT, Romero C, Kelleher D, Spreen W, LaFon S and the Abacavir Phase 2 Clinical Team. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS. 1998;12:F203-F209.
9. McFarland EJ, Harding PA, MaWhinney S, Schooley RT, Kuritzkes DR. In vitro effects of interleukin-12 on human immunodeficiency virus type 1 (HIV-1) specific cytotoxic T-lymphocyte lines from HIV-1 infected children. J Immunol. 1998;161:513-519.
10. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA; International AIDS Society-USA panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-843. (Prior recommendations published in 2004, 2002, 2000, 1998, 1997, 1996)